在怀孕期间患有肥胖症的患者中,根据BMI类增加来评估妊娠期体重增加的影响
相关实验视频
Updated: Jan 7, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
859
Maranda V Sullivan1, Jordan A Gillenwater2, Amanda J Young3
1Department of Maternal-Fetal Medicine, Geisinger Medical Center, Danville, PA, 17822, USA. marandavsullivan@gmail.com.
Maternal and child health journal
|December 22, 2025
概括
怀孕期间体重增加显著影响肥胖患者的结果. 妊娠期间增加的体重指数 (BMI) 类增加了周产期不良事件的风险,强调了目前基于BMI的管理的需要.
科学领域:
- 产科和妇科 产科和妇科
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 公共卫生和流行病学
背景情况:
- 怀孕期间的肥胖 (怀孕前的BMI≥30 kg/m2),与不良周产期结局的风险增加有关.
- 目前管理肥胖孕妇的指导方针通常考虑孕前的BMI,但怀孕期间BMI变化的影响需要进一步评估.
研究的目的:
- 评估怀孕期间增加的体重指数 (BMI) 类别对不良周产期结果的组合的影响.
- 根据怀孕期间的BMI变化与静态BMI类别的BMI变化来比较结果.
主要方法:
- 回顾性队列研究 (2009-2022年) 包括单独怀孕,怀孕前BMI≥30kg/m2.
- 排除标准:没有肥胖的怀孕或BMI等级下降的怀孕.
- 主要综合结局:胎儿生长异常,剖腹产,小水,多水和死产.
主要成果:
- 怀孕期间BMI从I类增加到II类与与维持I类BMI (aOR1.17) 相比,不良结果的几率更高.
- 这种增加 (I到II) 显示出与怀孕前的II类BMI相等的结果.
- 在怀孕期间从BMI II级增加到III级,与维持II级BMI相比,导致不良结果的几率显著增加 (aOR1.40).
结论:
- 对于肥胖的孕妇患者,管理建议应优先考虑当前的BMI状态,而不是怀孕前的BMI.
- 怀孕期间的BMI类别的变化,特别是增加,与不良周产期结果的风险增加有关.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Drug Dosing: Obese Patients
189
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
189
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
211
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
211
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
149
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
149

